Moody National Bank Trust Division Has $1.08 Million Stake in Evolent Health, Inc. (NYSE:EVH)

Moody National Bank Trust Division trimmed its holdings in shares of Evolent Health, Inc. (NYSE:EVH - Free Report) by 35.4% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 114,081 shares of the technology company's stock after selling 62,572 shares during the period. Moody National Bank Trust Division owned 0.10% of Evolent Health worth $1,080,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Pilgrim Partners Asia Pte Ltd bought a new stake in shares of Evolent Health during the fourth quarter worth $26,000. R Squared Ltd bought a new stake in shares of Evolent Health during the fourth quarter worth $31,000. AlphaQuest LLC raised its position in shares of Evolent Health by 21,650.0% during the fourth quarter. AlphaQuest LLC now owns 3,045 shares of the technology company's stock worth $34,000 after acquiring an additional 3,031 shares during the last quarter. Parkside Financial Bank & Trust grew its stake in shares of Evolent Health by 90.7% during the fourth quarter. Parkside Financial Bank & Trust now owns 4,957 shares of the technology company's stock worth $56,000 after purchasing an additional 2,358 shares during the period. Finally, AlphaCentric Advisors LLC acquired a new stake in shares of Evolent Health during the fourth quarter worth $61,000.

Analyst Ratings Changes

EVH has been the subject of a number of analyst reports. Piper Sandler reaffirmed an "overweight" rating and set a $16.00 price objective (down from $17.00) on shares of Evolent Health in a research note on Friday, February 21st. JPMorgan Chase & Co. decreased their price objective on Evolent Health from $13.00 to $12.00 and set an "overweight" rating for the company in a research note on Monday, March 10th. Truist Financial decreased their price objective on Evolent Health from $15.00 to $14.00 and set a "buy" rating for the company in a research note on Thursday, April 10th. JMP Securities reaffirmed a "market outperform" rating and set a $13.00 price objective on shares of Evolent Health in a research note on Monday, April 28th. Finally, UBS Group lifted their price objective on Evolent Health from $14.00 to $15.00 and gave the stock a "buy" rating in a research note on Friday, May 9th. One analyst has rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $17.79.

Evolent Health Trading Up 1.2%

EVH stock traded up $0.09 during midday trading on Friday, hitting $7.46. 1,653,591 shares of the company's stock were exchanged, compared to its average volume of 2,413,758. The company has a market cap of $875.80 million, a PE ratio of -9.10 and a beta of 1.04. The stock's fifty day moving average price is $9.21 and its 200-day moving average price is $10.19. Evolent Health, Inc. has a one year low of $7.06 and a one year high of $33.63. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.04 and a current ratio of 1.04.

Evolent Health (NYSE:EVH - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The technology company reported $0.06 EPS for the quarter, missing analysts' consensus estimates of $0.08 by ($0.02). Evolent Health had a negative net margin of 2.41% and a positive return on equity of 5.73%. The firm had revenue of $483.65 million during the quarter, compared to the consensus estimate of $460.15 million. During the same quarter last year, the firm earned $0.34 earnings per share. The business's revenue for the quarter was down 24.4% on a year-over-year basis. Research analysts predict that Evolent Health, Inc. will post 0.08 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Evolent Health news, Director Brendan B. Springstubb purchased 5,000 shares of the stock in a transaction on Tuesday, March 4th. The shares were purchased at an average price of $8.75 per share, with a total value of $43,750.00. Following the completion of the transaction, the director now directly owns 11,842 shares in the company, valued at $103,617.50. This represents a 73.08% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Seth Blackley purchased 55,225 shares of the stock in a transaction on Thursday, March 6th. The shares were acquired at an average cost of $9.01 per share, for a total transaction of $497,577.25. Following the transaction, the chief executive officer now owns 762,217 shares of the company's stock, valued at approximately $6,867,575.17. The trade was a 7.81% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 74,000 shares of company stock worth $666,315. Corporate insiders own 1.40% of the company's stock.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.